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Abstract
Background: The spatial distribution of vascular endothelial growth factor A (VEGF) is an important mediator of
vascular patterning. Previous experimental studies in the mouse hindbrain and retina have suggested that VEGF
alternative splicing, which controls the ability of VEGF to bind to heparan sulfate proteoglycans (HSPGs) in the
extracellular matrix (ECM), plays a key role in controlling VEGF diffusion and gradients in tissues. Conversely,
proteolysis notably by matrix metalloproteinases (MMPs), plays a critical role in pathological situations by releasing
matrix-sequestered VEGF and modulating angiogenesis. However, computational models have predicted that HSPG
binding alone does not affect VEGF localization or gradients at steady state.
Results: Using a 3D molecular-detailed reaction-diffusion model of VEGF ligand-receptor kinetics and transport, we
test alternate models of VEGF transport in the extracellular environment surrounding an endothelial sprout. We
show that differences in localization between VEGF isoforms, as observed experimentally in the mouse hindbrain,
as well as the ability of proteases to redistribute VEGF in pathological situations, are consistent with a model where
VEGF is endogenously cleared or degraded in an isoform-specific manner. We use our predictions of the VEGF
distribution to quantify a tip cell’s receptor binding and gradient sensing capacity. A novel prediction is that
neuropilin-1, despite functioning as a coreceptor to VEGF165-VEGFR2 binding, reduces the ability of a cell to gauge
the relative steepness of the VEGF distribution. Comparing our model to available in vivo vascular patterning data
suggests that vascular phenotypes are most consistently predicted at short range by the soluble fraction of the
VEGF distributions, or at longer range by matrix-bound VEGF detected in a filopodia-dependent manner.
Conclusions: Isoform-specific VEGF degradation provides a possible explanation for numerous examples of isoform
specificity in VEGF patterning and examples of proteases relocation of VEGF upon release.
Background
Vascular endothelial growth factor A (henceforth called
VEGF) is a critical pro-angiogenic factor secreted as
numerous splice isoforms that together regulate the phe-
notype and efficacy of growing vascular networks [1-7].
While the specific mechanism of this control is not fully
understood, both isoform-specific receptor binding at the
endothelial cell surface [8,9] and differences in the iso-
forms’ spatial patterning [6,7,10-13] are thought to be
key. We have previously published studies of the impact
of isoform-specific receptor binding [8,14], and here we
focus on the spatial patterning. The spatial distribution
of VEGF isoforms is thought to be mediated by their
interactions with heparan sulfate proteoglycans (HSPGs)
in the extracellular matrix (ECM), and by proteases such
as the matrix metalloproteinases (MMPs), which can
cleave both VEGF [7] and the ECM [15]. Proteases have
been shown to have important roles in inducing VEGF-
mediated angiogenesis and tumorigenesis [7,16-20].
While it may seem intuitive that ECM binding regulates
VEGF diffusion, computational studies suggest that at
steady state, simple sequestration by HSPGs may have lit-
tle effect on the soluble VEGF distribution. The specific
mechanisms by which HSPG binding and proteolytic
release regulate VEGF diffusion in vivo are therefore not
yet fully understood, and we explore this here.
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VEGF164, and VEGF188 (human VEGF is one amino acid
longer: VEGF121,V E G F 165,V E G F 189)[ 3 ] ;l o n g e ri s o -
forms include C-terminal motifs that increase binding to
heparin and HSPGs in the ECM [21,22]. This increased
matrix affinity can reduce the effective diffusivity of the
isoform, altering the spatial gradient. For example,
transgenic mice expressing only VEGF120,a ni s o f o r m
lacking HSPG affinity [23], show a shallow VEGF gradi-
ent in the developing hindbrain [13] and retina [12],
whereas wildtype mice, which predominantly express
the heparin-binding VEGF164, have a VEGF spatial dis-
tribution that is markedly more localized (Figure 1A).
Systems secreting VEGF188 show the greatest levels of
ECM and basement membrane VEGF deposition [6,24].
As noted above, VEGF sensed by endothelial VEGF
receptors has two isoform-specific components: the spa-
tial differences between VEGF isoforms; and the isoform
specificity of binding to the receptors themselves as dis-
cussed below. These give rise to a spectrum of isoform-
dependent vascular phenotypes (Figure 1B). VEGF regu-
lates sprouting angiogenesis at the level of tip cell filopo-
dial guidance and migration and stalk cell proliferation
[12]. Systems (mice or tumor xenografts) secreting only
t h ed i f f u s i b l eV E G F 120 usually develop wide, tortuous,
malformed vessels with infrequent branching (Figure 1B)
[6,12,13]. This phenotype suggests excessive proliferation
and an insufficiency in sprout guidance. On the other
hand, VEGF188 alone gives rise to vessels that are thin
and numerous and have high branching density [3,6].
VEGF164, similar to wild type mice, displays intermediate
behaviour [4,6,13,25]. While these behaviours are
thought to be primarily dependent upon the receptor tyr-
osine kinases VEGFR2 (KDR/Flk-1) [12], VEGFR1 (Flt-1)
also seems to play an important but not yet fully under-
stood role, in part by modulating VEGFR2 signaling [26].
VEGF isoforms also differentially bind to neuropilin-1
and -2 (NRP1 and NRP2), a class of semaphorin corecep-
tors that function as coreceptors for VEGFR2. Neuropi-
lin-1, for example, can greatly enhance the signaling of
VEGF165 relative to VEGF121 [23,27].
Proteolytic release of VEGF from the matrix seems to
biologically mimic secretion of shorter isoforms (Figure
1B). For example, VEGF120 elicits vascular effects at
greater distances away from the source of secretion than
VEGF164 [6,12]; similarly, VEGF release by the protease
MMP9 enhances VEGFR2 binding in quiescent vascula-
ture by increasing soluble (diffusible) VEGF levels [16],
activating tumorigenesis through the angiogenic switch
[16,18,19]. Tumor xenografts expressing only the cleaved
isoform VEGF113 have large dilated vessels [7]. Inhibiting
MMP9 results in markedly localized VEGF distributions
reminiscent of VEGF164 or VEGF188, with higher levels of
matrix-bound VEGF [6,13,19]. Secretion of a synthetic
VEGF164 that is resistant to proteolysis (VEGF164Δ108-118)
induces vascular patterning phenotypes similar to that of
VEGF188 alone, specifically high vascular densities [7]
(Figure 1B). While the direct cleavage of VEGF’s C-term-
inal heparin-binding and NRP1-binding domain is the
most accepted mechanism of release (plasmin produces
VEGF110 from VEGF165 [23]; MMP3 produces VEGF113
from VEGF164 [7]), cleavage of HSPGs and ECM by pro-
teases or heparinases is also a potent release mechanism
[15,28-30], but one that liberates intact VEGF. Recently,
degradation of soluble VEGF inhibitors such as connec-
tive tissue growth factor and soluble VEGFR1 (sVEGFR1)
has also been suggested to regulate VEGF [31-33].
The effects of protease-mediated VEGF release are not
fully understood. VEGF164Δ108-118- and VEGF188-expres-
sing tumors show similar intratumoral vessel architectures;
however, paradoxically, their ability to enhance tumor
growth are vastly different: VEGF188 either significantly
Figure 1 VEGF isoform patterning and its effects on vascular patterning. VEGF is patterned in tissues in an isoform-dependent manner,
with loss of heparin binding affinity translating to less localized, broader distributions [12,13]. A, Isoform specificity of VEGF distribution in the
developing mouse hindbrain for mice transfected to express VEGF120 versus wildtype mice, which express predominantly VEGF164 [94]. B,
Differences in VEGF localization are thought to give rise to vascular phenotypes that vary with the VEGF isoform, in a monotonic fashion. Larger
isoforms, i.e. greater heparin binding affinity, give rise to sprouts that have greater filopodial directionality and vessels with greater branching
density and smaller diameters. Similarly for VEGF proteolysis (red text): in tumors, loss of proteolysis exhibits similar features as VEGF188-secreting
tumors, while VEGF120-secreting tumors have similar features as tumors secreting precleaved VEGF [6,7].
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while VEGF164Δ108-118 results in tumor hyperproliferation
[7]. Similarly, while most studies implicate MMPs, e.g.
MMP9, in pro-angiogenic and carcinogenic behaviors
through VEGF [15,16,20,29,32,33], in others, VEGF pro-
teolysis results in an angiogenic response that is uncoordi-
nated and ineffective [17], leading to lower vessel density
and decreased tumor growth [7].
It is not fully understood how the spatial patterning of
different VEGF isoforms and the processing of VEGF by
proteases control endothelial behavior, however several
possibilities have been suggested by experiments
[7,12,34]. For example, increased matrix-bound VEGF in
tissues (due to expression of longer isoforms or inhibition
of proteolysis) may increase branching behavior and
decrease vessel diameters by increasing p38/MAPK sig-
naling [7,35]. Alternatively, low levels of soluble VEGF
may independently increase sprouting behavior [36]. On
the other hand, vascular patterning might arise due to
neuropilin-1-dependent activation of p38/MAPK signal-
ing [34], supported by the high affinity of VEGF165 and
VEGF189 for NRP1 [37]. Finally, steep VEGF isoform gra-
dients may improve tip cell filopodial stability while miti-
gating stalk cell proliferation [12].
Whatever the dominant signaling modality that guides
vascular patterning, it appears from experimental data to
have two particular properties. First, the seemingly mono-
tonic increase in vascular density and decrease in vessel
diameter with VEGF isoform length (Figure 1B) suggests
that the critical feature of the VEGF distribution that con-
trols vascular behavior also varies in a monotonic fashion.
Monotonicity is also evident in the similar vascular pheno-
types arising from mice dually expressing VEGF120 and
VEGF188, and those only expressing VEGF164, at the same
total rate [6,13]. Second, increased VEGF cleavage has the
opposite effect to increased HSPG binding [6,7] (Figure
1A). All of the above modalities seem to support both con-
ditions; for example, among the isoforms, VEGF188 would
be expected to have the highest levels of matrix-bound
VEGF [24], lowest levels of soluble VEGF [21,22], most
directional gradients [13], and possibly greatest NRP1 affi-
nity [37]. Similarly, VEGF cleavage prevents VEGF binding
to HSPGs and NRP1 [23], and by solubilizing VEGF
should lead to greater diffusion.
To separate out the above effects, we seek to develop a
precise understanding of the effects of HSPG binding
and VEGF proteolysis on the VEGF distribution by creat-
ing a computational model. The model should replicate
key experimental observations regarding the VEGF distri-
bution (summarized in Table 1): longer isoforms with
stronger heparin binding affinity have higher degrees of
localization (shorter propagation distances and higher
local peaks) (Figure 1A) [13]; increased heparin binding
affinity results in greater levels of matrix deposition and
decreased levels of soluble-phase VEGF [7,21,22,24,38];
and VEGF-cleaving proteases should reverse these pat-
terns [7,16,19]. The inverse relationship between soluble
and matrix-bound VEGF gives rise to the question of
whether total VEGF is conserved in vivo. While this is
expected in vitro [22,39], and was also seen by certain
studies in vivo [7,19], other studies found significantly
higher total VEGF levels for VEGF165-expressing systems
[25,39].
The current study extends our work on understanding
the nature of VEGF transport in angiogenesis [40-44].
Among the numerous mechanisms of proteases modu-
lating VEGF, we focus on VEGF cleavage, which we
have previously studied [44]. Our model describes a
sprout situated in a VEGF concentration gradient, to
represent a range of biological systems, e.g. the hypoxic
front of the hindbrain, tumor, or retina.
We use the computational model (Figure 2) to under-
stand mechanisms that might allow isoform-dependent
VEGF localization and proteolytic redistribution to arise.
Using a VEGF-VEGFR kinetic binding model, we investi-
gate how VEGF signals may be detected by endothelial
cells, e.g. soluble or matrix-bound VEGF, and the impact
of NRP1. The results suggest that the system must exhi-
bit isoform specificity in VEGF clearance or degradation:
along with longer isoforms binding to the ECM with
greater affinity, the longer isoforms must also be cleared
or degraded from the soluble fraction at faster rates.
Methods
Model Formulation
To study the role of different isoforms and VEGF pro-
teolysis on the VEGF distribution, we constructed a 3D
reaction-diffusion-based computational model of VEGF
transport. The model is centered on a capillary sprout
containing a single endothelial tip cell followed by stalk
cells (Figure 2A), to study the VEGF concentration pro-
file and gradients in the vicinity of the sprout, and to
understand the receptor signaling and gradients detected
Table 1 Goals of computational model to match with
experimental observations
VEGF Metric Effect of a decrease in
isoform length
Effect of VEGF
cleavage
Level of Soluble VEGF ↑ [21] ↑ [7]
Level of Bound VEGF ↓ [24] ↓ [19] *
Level of Total VEGF = [7] * = [7,19] *
Magnitude of soluble
VEGF gradients
↓ [13] ↓ [17]
Spatial Range of soluble
VEGF
↑ [12] ↑ [17]
Note the concordance of the outcomes of decreased isoform length and VEGF
cleavage.
* hypothesized, or some supporting evidence, but no definitive experimental
confirmation
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lial tip cell. To dissect the behavior of individual iso-
forms, we consider separate systems expressing a single
isoform in isolation, similar to those tested experimen-
tally in developmental and tumor models.
A schematic of the VEGF transport and reaction is pre-
sented in Figure 2B. In our model, we label our VEGF
using the human isoforms nomenclature and represent
cleaved VEGF by VEGF114, which is the predicted MMP-
cleavage product of human VEGF [7]. While Figure 2 pri-
marily details the interactions of secreted VEGF165,w e
also separately consider VEGF121 and VEGF189,a n d
hypothetical isoforms of intermediate lengths and prop-
erties. These intermediate isoforms are generated by
smoothly varying the relevant parameters: HSPG affinity,
NRP1 affinity, and ability to bind the VEGFR1-NRP1
complex. While VEGF121 has weak affinity to NRP1 [45],
we assume it does not bind NRP1, and this does not
change our results [43]. Intact (unproteolysed) VEGF189
may be unable to bind VEGFR2 [46], but binding of long
isoforms of VEGF to VEGFR2 is predicted to be low in
our model due to degradation and cleavage; cleaved
VEGF represents the majority of VEGFR2 binding in this
case.
We assume that VEGF is secreted from the leading
face of the cylindrical domain and is cleared by two
mechanisms: internalization by the sprout’sV E G F
receptors; and clearance at the trailing edge of the
domain (which physiologically represents the effects of
both diffusion and internalization by downstream vascu-
lature). As a base model (Figure 2, 3), we consider that
the sprout expresses all three VEGF receptors, in a com-
bination where excess NRP1 plays a potentiating role for
VEGF165 binding to VEGFR2 [27]. The sprout is situated
in a cylindrical domain consisting of an acellular extra-
cellular matrix (ECM) that contains uniform HSPG
binding sites for VEGF. For VEGF proteolysis, we
assume a uniform, single-step irreversible first-order
MMP-mediated cleavage of VEGF to VEGF114 (devel-
oped previously in [44]). The dynamics of protease acti-
vation and inhibition have been studied in the past
[47-49], but are neglected here because of uncertainties
in the transport of the protease itself.
We have previously shown that the thin basement mem-
brane layer does not significantly affect VEGF diffusion
near the sprout [44], and thus do not consider the base-
ment membrane here. As in previous models [41,42,50],
receptors are considered pre-dimerized and binding of the
ligand is a reversible single-step reaction; in addition,
internalization and receptor insertion are balanced to keep
plasma membrane receptor levels constant. Finally, though
matrix-bound VEGF may be relevant to VEGFR2 activa-
tion [35], our model only considers receptors binding to
soluble VEGF.
Figure 2 Schematic diagram of computational model. We simulate the transport of VEGF in an idealized microenvironment around a
sprouting vessel. The above diagram, the base model, includes the processes of VEGF secretion and clearance (A), VEGF binding to sprout
surface receptors (B), and VEGF binding to HSPGs and VEGF proteolysis in the interstitium (C). The domain is an axially-symmetric tissue cylinder,
160 μm in length and 50 μm in radius, selected to mimic in vivo sprout spacing. The model considers the isoforms VEGF121, VEGF165, and
VEGF189 in isolation to compare to single-isoform-expressing in vivo systems, and allows for cleavage of isoforms into VEGF114, the MMP-cleavage
product. Receptor signaling is modeled with the isoforms’ interactions with VEGFR1, VEGFR2, and NRP1 (B). While the reactions are shown
primarily for VEGF165, isoforms VEGF121 and VEGF189, where bracketed, participate in similar reactions. VEGF and receptor-binding gradients are
measured between the front and rear of the tip cell (indicated in gray arrowheads) (A). Extensions of this model explored here include gradients
of HSPG and VEGF degradation (Figure 4).
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plexity, to understand the mechanisms behind gradient
formation. The model components as described above -
diffusion, receptor binding, proteolytic processing - com-
prise the “HSPG-binding-only” model. This is so named to
contrast with other models that add additional processes
relevant to VEGF patterning in vivo: patterned HSPG gra-
dients (the “HSPG-gradient” model) and VEGF degrada-
tion. VEGF degradation is defined here as any interstitial
process that destroys VEGF activity, without generating an
active cleavage fragment as proteolysis does. As with pro-
teolysis, degradation was characterized by a first-order rate
constant, kdeg. The study of degradation was done with
two models: one assuming that degradation affects only
soluble VEGF (the “soluble VEGF degradation” model);
and one in which both soluble and matrix-bound VEGF
are degraded (the “matrix-sequestered VEGF degradation”
model). We will see later that the soluble VEGF degrada-
tion model, in which HSPG-bound VEGF is protected
from degradation, is effectively isoform-independent
degradation; while degradation of HSPG-bound VEGF
results in isoform-dependent degradation. Longer isoforms
have higher degradation (despite having the same rate
constant) due to longer retention times.
In studying receptor binding, we incorporate a sprout
expressing VEGFR1, VEGFR2, and NRP1. This sprout
can itself influence VEGF transport (by receptor-
mediated uptake), and to study the patterning of VEGF
that would arise only by diffusion, matrix binding, pro-
teolysis and degradation, we also considered a variant of
the model that contains no sprout.
VEGF/Protease Transport and Reactions
VEGF biochemical reactions and transport processes are
described by partial differential equations with appropriate
boundary conditions. The computational domain consists
of two components: the interstitium, into which VEGF is
secreted, and a sprout surface layer, on which VEGF cap-
ture by the receptors is modeled. Upon secretion from the
leading edge of the domain (z = +L), VEGF transport
within the domain is governed by the mass balance
(VEGF165 equation shown; similar equations for other iso-
forms):
∂[V165]
∂t
=D 165∇2[V165] − k
V
P[V165] − kV
deg[V165]
−
k
V,H
on
KECM
[V165][H] + k
V,H
off [V165H]
(1)
Figure 3 Steady-state distribution of VEGF is not dependent upon interstitial HSPGs.U s i n gt h em o d e l ,w ec a l c u l a t e dt h es t e a d y - s t a t e
distribution of VEGF165, in the presence (A) and absence (B) of interstitial HSPGs, assuming no interstitial proteases, and no other differences
between the two systems. The VEGF distribution was initialized so as to have a mean soluble VEGF concentration of ~1 pM and a fractional
gradient of ~5%/40 μm at the leading edge of the sprout (z = 0); HSPG binding and receptor-mediated internalized were calculated. Conditions
of the model are defined in Table 4: HSPG = 750 nM, VEGFR1 = VEGFR2 = 10
4/cell, NRP1 = 3*10
4/cell; secretion and clearance of the soluble
fraction occurred at q = 5.27·10
-5 molec/μm
2·sec and kclear = 0.0399 μm/sec. Traces of steepest descent arising from r = 0, 6, 20, and 38 μm and
z=8 0μm are overlaid to demonstrate the effect of internalization on the curvature of the VEGF distribution around the sprout. We also
measured VEGFR1, VEGFR2, and NRP1 receptor occupancies, absolute and fractional gradients, and the sensitivity of relative gradient detection
are given for each case. The sensitivity is defined as the ratio of the receptor gradient to the ligand gradient.
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tion of the soluble fraction of VEGF165, assuming an iso-
tropic porous matrix with available volume fraction
KECM.D 165 is the effective diffusion coefficient for
VEGF165 in the matrix; [H] is the density of VEGF-bind-
ing sites, with reaction rate constants, kon
V,H and koff
V,H.
kP describes first-order net rate of proteolysis, and kdeg
describes first-order degradation of soluble VEGF. We
assume that kP and kdeg are spatially uniform. The
values of these parameters are given in Table 2 and
described further below.
Cleaved VEGF (VEGF114) is generated from the proteo-
lysis of free VEGF or matrix-bound VEGF (Figure 2C).
∂[V114]
∂t
=D 114∇2[V114] − kV
deg[V114]
+k
V
P[V165]+k
VH
P [V165H]
(2)
VEGF proteolysis also produces an HSPG-binding C-
terminal fragment [23] that maintains heparin affinity,
but we do not include it explicitly as HSPGs are not
saturated (i.e. [V]<< Kd
V,H). The matrix components,
HSPG and VEGF-HSPG do not diffuse:
∂[H]
∂t
= −
k
V,H
on
KECM
[V165][H] + k
V,H
off [V165iH]
+k
VH
P [V165H]
(3)
∂[V165H]
∂t
=
kon
KECM
[V165][H] − koff[V165H]
− kP[V165H] − kVH
deg[V165H]
(4)
Boundary conditions for VEGF reaction at the cell surface
VEGF and cleaved VEGF are coupled to the cell-surface
VEGF receptor population through the specification of
boundary conditions. These boundary conditions equate
the flux of VEGF perpendicular to the cell surface, J =
-D·∂V/∂n, with the rate of reaction at the cell surface.
For VEGF165 and VEGF189, these reactions include bind-
ing to VEGFR2, VEGFR1, and NRP1, while for VEGF114
and VEGF121, binding occurs to VEGFR2, VEGFR1, and
the VEGFR1-NRP1 complex (rate parameters for the
individual isoforms are given in Table 2).
D165
∂[V165]
∂n
=k
V, R2
on [V165][R2] − k
V, R2
off [V165R2]
+k
V, R1
on [V165][R1] − k
V, R1
off [V165R1]
+k
V, N1
on [V165][N1] − k
V, N1
off [V165N1]
(5)
D114
∂[V114]
∂n
=k
V, R2
on [V114][R2] − k
V, R2
off [V114R2]
+k
V, R1
on [V114][R1] − k
V, R1
off [V114R1]
+k
V, N1
on [V114][R1N1] − k
V, N1
off [V114R1N1]
(6)
Equations describing the VEGF receptors are given as
a system of ordinary differential equations over the
sprout surface. In addition to describing VEGF binding
to the receptors, they describe the continual balance
between secretion of unligated VEGF receptors (at a
rate sR) and internalization (kint), VEGF165 bridging of
VEGFR2 and NRP1, VEGFR1/NRP1 coupling (kc)a n d
uncoupling (kuc), and VEGF114 binding to the VEGFR1-
NRP1 complex. Note that VEGF121 and VEGF189 terms
Table 2 Kinetic Parameters
Isoforms Involved Reaction Forward
kon,k c,k int
Reverse
koff,k uc
Keq Ref.
Cell-surface Reactions
121, 165 Binding VEGF to VEGFR2 1·10
7 M
-1s
-1 0.001 s
-1 100 pM [42]
All Binding VEGF to VEGFR1 3·10
7 M
-1s
-1 0.001 s
-1 33.3 pM [42]
165, 189 Binding VEGF to NRP1 3.2·10
6 M
-1s
-1 0.001 s
-1 312 pM [42]
165 Binding VEGF165-VEGFR2 to NRP1 3.1·10
6
[10
15 μm
2/(mol·s)]
0.001 s
-1 323
mol/10
15 μm
2
[42]
165 Coupling VEGF165-NRP1 to VEGFR2 1·10
7
[10
15 μm
2/(mol·s)]
0.001 s
-1 100
mol/10
15 μm
2
[42]
121, Cleaved Coupling VEGFR1 to NRP1 or
Coupling VEGF114-VEGFR1 to NRP1
1·10
7
[10
15 μm
2/(mol·s)]
0.01 s
-1 1000
mol/10
15 μm
2
[42]
- Internalization, kint 2.8·10
-4 s
-1 - - [42]
- Insertion, sR2,s R1,o rs N1 e.g., kint.·[R2]
total - - calculated
ECM Reactions
165 VEGF165 to HSPG 6.06·10
4 M
-1s
-1 0.01 s
-1 165 nM [63]
189 VEGF189 to HSPG 1.18·10
6 M
-1s
-1 0.01 s
-1 8.5 nM Figure S1.1
All Degradation rate, kdeg (only Figs. 4C,D; 8A) 0.001 s
-1 - - assumed
All Protease activity, kP (only Figs. 6; 7A; 8A) 2.8·10
-4 s
-1 - - assumed
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diffuse along the cell surface.
d[R1]
dt
=s R1 − k
R1
int[R1]
−
k
165,R1
on
KBM
[V165][R1] + k
165,R1
off [V165R1]
−
k
114,R1
on
KBM
[V114][R1] + k
114,R1
off [V114R1]
− k
R1,N1
c [R1][N1] + k
R1,N1
uc [R1N1]
(7)
d[R2]
dt
=s R2 − k
R2
int[R2]
−
k
165,R2
on
KBM
[V165][R2] + k
165,R2
off [V165R2]
−
k
114,R2
on
KBM
[V114][R2] + k
114,R2
off [V114R2]
−k
165N1,R2
c [V165N1][R2] + k
165N1,R2
uc [V165R2N1]
(8)
d[N1]
dt
=s N1 − k
N1
int[N1]
−
k
165,N1
on
KBM
[V165][N1] + k
165,N1
off [V165N1]
− k
165R2, N1
c [V165R2][N1] + k
165R2,N1
uc [V165R2N1]
− k
114R1, N1
c [V114R1][N1] + k
114R1,N1
uc [V114R1N1]
− k
R1,N1
c [R1][N1] + k
R1,N1
uc [R1N1]
(9)
d[R1N1]
dt
= −k
VR1N1
int [R1N1]
+k
R1,N1
c [R1][N1] − k
VR1,N1
uc [R1N1]
−
k
114, R1N1
on
KBM
[V114][R1N1] + k
114, R1N1
off [V114R1N1]
(10)
d[V165R1]
dt
= −k
165R1
int [V165R1]
+
k
165, R1
on
KBM
[V165][R1] − k
165, R1
off [V165R1]
(11)
d[V165R2]
dt
= −k
165R2
int [V165R2]
+
k
165, R2
on
KBM
[V165][R2] − k
165, R2
off [V165R2]
−k
165R2,N1
c [V165R2][N1] + k
165R2,N1
uc [V165R2N1]
(12)
d[V165N1]
dt
= −k
165N1
int [V165N1]
+
k
165, N1
on
KBM
[V165][N1] − k
165, N1
off [V165N1]
−k
165N1,R2
c [V165N1][R2] + k
165N1,R2
uc [V165R2N1]
(13)
d[V165R2N1]
dt
= −k
165R2N1
int [V165R2N1]
+k
165R2, N1
c [V165R2][N1] − k
165R2,N1
uc [V165R2N1]
+k
165N1,R2
c [V165N1][R2] − k
165N1,R2
uc [V165R2N1]
(14)
d[V114R1]
dt
= −k
114R1
int [V114R1]
+
k
114, R1
on
KBM
[V114][R1] − k
114, R1
off [V114R1]
−k
114R1,N1
c [V114R1][N1] + k
114R1,N1
uc [V114R1N1]
(15)
d[V114R2]
dt
= −k
114R2
int [V114R2]
+
k
114, R2
on
KBM
[V114][R2] − k
114, R2
off [V114R2]
(16)
d[V114R1N1]
dt
= −k
114R1N1
int [V114R1N1]
+
k
114, R1N1
on
KBM
[V114][R1N1] − k
114, R1N1
off [V114R1N1]
+k
114R1,N1
c [V114R1][N1] − k
114R1,N1
uc [V114R1N1]
(17)
External Boundary conditions for VEGF secretion and
clearance
The computational domain is assumed to be representa-
tive of its surrounding tissue in the radial direction.
T h u s ,w eu s ean o - f l u xc o n d i t i o n ,∂V/∂r=0a tr=
Redge. The VEGF gradient was specified by secretion of
uncleaved VEGF at z = +L using the Neumann BC,
-DV·∂[V]/∂z = -q, and a first-order VEGF clearance at z
=- L ,- D V·∂[V]/∂z=- k clear[V]. The secretion rate q and
kclear were pre-calculated to generate the desired VEGF
distribution in the absence of proteases, i.e. a concentra-
tion V0 at z = 0 and a VEGF gradient, g0 over the
domain length. For cleaved VEGF, there was no secre-
tion, but there was clearance. Protease activity and
degradation were assumed to be uniform.
The volume-averaged clearance rate of soluble VEGF
in our model, kclear/(2L) ~ 2.49·10
-4 s
-1, is similar in
magnitude to clearance times in vivo [51] and represents
internalization by downstream cells and transvascular
permeability.
Steady-state assumption and consequences
The steady-state approximation assumed in our simula-
tions is justified because VEGF diffusion and reaction,
which our model considers, occur much more rapidly
than the structural changes in vessels and parenchymal
cells, which may take days to weeks. Transients in the
VEGF distribution are limited by the residence time of
Vempati et al. BMC Systems Biology 2011, 5:59
http://www.biomedcentral.com/1752-0509/5/59
Page 7 of 24VEGF in tissue, which has been experimentally [51-53]
and theoretically [42] shown to be ~1 h or less. The
steady nature of the VEGF distribution has been experi-
mentally confirmed in the hindbrain, where the VEGF
distribution is relatively unchanged over an 18 h win-
dow [13] and still maintains isoform specificity. If transi-
ent diffusion does contribute to the specificity of VEGF
gradients, we would expect vascular patterning to lose
its isoform-dependence over long periods, which is not
seen either in the retina (1 week [12]) or in tumors (sev-
eral weeks [6,7,19]). The same may be true for in vitro
and ex vivo systems (1-3 days, [7,54]).
The VEGF transport equations can be simplified at
steady state. We perform the analysis for VEGF165, but the
analysis is applicable to any isoform. In the absence of pro-
teases, VEGF is in equilibrium with HSPG (kon[V][H] =
koff[VH]) thus the VEGF diffusion equation reduces to:
∇2[V] = 0 (20)
This equation states that VEGF transport is not influ-
enced by HSPG binding. In the presence of proteases,
VEGF165 can be converted to VEGF114, and summation
of the VEGF165 and VEGF114 equations and neglecting
minor variations in the intrinsic diffusivity of the two
isoforms, leads to:
∇2([V165]+[ V 114]) =0 (21)
Thus, the total soluble VEGF is specified by the same
equation regardless of the presence or distribution of
VEGF-cleaving proteases. If receptor-mediated internali-
zation is identical between the isoforms (e.g. in the
absence of NRP1), total soluble VEGF should not be
altered by proteases.
Another important quantity, matrix-bound VEGF, can
be calculated using the relation, [H] = [H]Total -[ V H ] .
Assuming a uniform protease distribution, with proteo-
lysis rate kP, we obtain
[VH] =
kon[V][H]Total
koff +k P +k on[V]
(22)
Note that for typical parameters used in this study, koff
>> kP >> kon[V], we can approximate VEGF/HSPG
binding by [VH] ~ [V][H]Total/Kd ( i . e .t h a t[ V H ]i s
directly proportional to [V] and total HSPG). The
steady-state distribution of the soluble fraction of VEGF
can thus be described by:
1
[V]
∇2[V] =
kP
D

1+
kon[H]Total
koff +k P

=
kP
DEff
(23)
Thus, VEGF proteolysis is enhanced not only by the
rate of proteolysis, kP, but also by matrix binding, which
decreases VEGF’s effective diffusivity, DEff =D / ( 1+[ H ]
Total/Kd). As a result, matrix binding potentiates VEGF
proteolysis.
Numerical Methods for VEGF Calculations
The transport of VEGF and the dynamics of HSPG were
solved using the finite volume method in cylindrical coor-
dinates (z and r), Figure 2. The control volume spacing in
the z direction was 8 μm. In the r direction, one voxel was
used to represent the sprout radius, from r = 0 to r =
Rsprout; for r ≥ Rsprout (outside the sprout surface), spacing
was 4-8 μm. A finer grid produces consistent results differ-
ent by less than 5% and does not alter qualitative conclu-
sions. Heterogeneous reactions at the cell surface were
approximated as homogenous reactions, using a basement
membrane layer formulation given previously [40].
The steady-state solution was obtained by solving the
transient solution from the initial conditions until a rela-
tive convergence of 10
-7 was achieved at each node. First-
order temporal derivatives were discretized using a first
order fully-implicit scheme, while the second-order spatial
derivatives were discretized using a second order central
difference method. Nonlinear solution of the equations
was found by iteration using the successive over-relaxation
(SOR) update formulation and a Red-Black node ordering
[55]. Simulations were run on a personal computer using
custom code written for Matlab 7.6.0.
Model Implementation and Initial Conditions
Because the cellular internalization of VEGF creates a
region of VEGF depletion near the sprout, to be consis-
tent we ran each simulation with an initial VEGF gradi-
ent in the absence of proteases or degradation. We first
imposed Dirchelet BCs satisfying the overall domain
gradient of VEGF, g0, and mean VEGF concentration V0
at z = 0 (see Parameters): at z = +L, [V165]=V 0·(1
+g0·L/Ltip), at z = -L, [V165]=V 0·(1-g0·L/Ltip)), setting
any degradation and proteolysis rates to be zero. This
s i m u l a t i o nc a nb ed o n ei nt h ea b s e n c eo fH S P G st o
reach convergence more quickly since HSPGs have no
influence on steady-state soluble VEGF under these con-
ditions (see previous section). After equilibration of dif-
fusion and the VEGF receptors, Dirichlet BCs were
converted into Neumann BCs specified by q and kclear,
defined using the following formulas:
q ·
Re d g e 
0
rdr =
Re d g e 
0
D165
∂[V165]
∂z

 

z=+L
rdr (18)
kclear ·
Redge 
0
[V165]rdr =
Redge 
0
D165
∂[V165]
∂z

 

z=−L
rdr (19)
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equations only approximately specify the conditions, g0
and V0; however this is sufficient for our study. After
this step, we incorporated HSPGs and VEGF-HSPG
complexes at equilibrium, any degradation terms and
proteolytic reactions to arrive at the predicted steady-
state spatial distribution.
Geometrical and Transport Parameters
The tissue (cylindrical computational domain) is 160 μm
long (L = 80 μm) and 100 μm in diameter (Redge =5 0
μm) (Table 3, Figure 2A). The sprout is a cylinder from
z=- 8 0μmt oz=0w i t har a d i u so fR sprout =2μm.
These dimensions were chosen to reflect the average
sprout size and sprout-to-sprout distance based on
micrographs of sprouting vasculature [12,13,56].
The matrix composition affects both the diffusivity
and the available volume for VEGF transport. We esti-
mate the available volume fraction of the ECM as 0.85
consistent with experimental data on transport studies
of dextran in cellularized agarose gels [57]. Diffusivity
was calculated by estimation of the aqueous diffusivity,
Daq, at 37°C using data from Berk et al. and the Stokes-
Einstein relation [58,59]. The hindrance of the matrix
was then approximated using Ogston’s relation, assum-
ing a matrix composition of 14% v/v collagen fibrils (rh
= 20 nm), 0.078% v/v GAG chains (rh =0 . 5 5n m )a si n
[60]. Finally, we corrected for the increased viscosity
due to proteinacious interstitial solution (20.6 g protein/
L) [61], resulting in D165 = 68.6 μm
2/s. Despite a slight
error, we standardized the results of the different VEGF
isoforms by assuming D165 for also VEGF114,V E G F 121,
and VEGF189. Receptor movement is neglected as diffu-
sivity along the cell surface, D ~ 0.01 μm
2/s [62] is
much slower than reactions at the cell surface; the Dam-
köhler number is Da = koff·Ltip
2/D = 160.
Kinetic Parameters for Reactions
To estimate the binding of VEGF165 to HSPGs, we used
binding rates of bFGF to HSPGs (kon =4 . 2 · 1 0
5 M
-1s
-1,
koff =0 . 0 1s
-1,K d = 23.8 nM) [63] and adjusted kon to
match Kd estimates of VEGF165 binding to heparin, Kd
~ 165 nM [38,64]. VEGF189 binds to heparin and
HSPGs more strongly than does VEGF165, however no
estimate for its Kd had been made. Based on extrapola-
tion of VEGF165 heparin elution data (described in more
detail in Additional file 1, section S1; Figure S1.1B), we
estimated a lower limit for Kd of 8.5 nM. VEGF121 and
VEGF114 d on o tb i n dt oH S P G[ 2 3 ] .T h eo v e r a l lr a t eo f
VEGF cleavage by proteases in tissues is not known; but
we assumed a rate that produces significant effects for
our model parameters, kP =2 . 8 · 1 0
-4 s
-1 (time-scale of
1 hr), which is similar to VEGF clearance rates in vivo.
We previously characterized kinetic parameters for the
binding of VEGF to VEGFR1, VEGFR2, and NRP1, and
for the coupling of the receptors (see Table 2) [42].
While VEGF165 has several fold greater affinity for
VEGFR2 (in the presence of HSPG) than VEGF121
[23,38,65] and VEGF121 may bind NRP1 with low affi-
nity [45], we assume that the differences in the isoform
binding to receptors are due to differences in NRP1
binding: no binding for VEGF121; affinity for VEGF189
higher than that of VEGF165 in proportion to the iso-
forms’ HSPG affinity. The behavior of cleaved VEGF110
(and presumably VEGF114) has been shown to be identi-
cal to that of VEGF121 [23] indicating similar receptor
kinetics to VEGF121. Finally, we assume receptors are
internalized at a rate, kint, independent of VEGF binding
[66] and that each VEGFR is maintained at a constant
level, i.e. sR2 =k int·[R2]Total.
As described above, we studied a hypothetical conti-
nuum of VEGF isoforms with properties intermediate
between the three isoforms: we varied VEGF receptor
binding parameters along this continuum proportionally
to the isoforms’ affinity for HSPGs. Two opposing effects
needed to be accounted for: the ability of VEGF to couple
VEGFR2 and NRP1 and the ability of VEGF to bind to the
VEGFR1-NRP1 complex. Thus the VEGF-NRP1 binding
rate was kon
V,N1 =k on
165,N1·(Kd
165,H/Kd
V,H). The coupling
rate, kc, between VEGF-VEGFR2 and NRP1 was also
increased by the same factor to preserve equilibrium. In
contrast, VEGF binding to the VEGFR1-NRP1 complex
and NRP1 coupling to the VEGF-VEGFR1 complex was
higher for shorter isoforms, with k’forward =k forward·(Kd
V,H
-K d
165,H)/Kd
165,H and kreverse unchanged, for isoform
HSPG binding affinities greater than Kd
165,H = 165 nM
Table 3 Physical and Transport Parameters
Parameter Value Ref.
Radius of domain, R 50 μm Assumed
Half-Length of domain, L 80 μm Assumed
Length of tip cell, Lcell 40 μm [12]
Radius of sprout, Rsprout 2 μm [12]
Tip cell surface area: 515 μm
2 calculated
Diffusivities, D114, D121, D165,D 189 68.6 μm
2/s (see Methods) estimated
Local Available Volume Fraction of the extracellular matrix, KECM 0.85 [57]
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has no binding to VEGFR1-NRP1).
A degradation rate constant of kdeg =1 0
-3 s
-1 was used
to estimate the impact of significant degradation. As we
will see, total degradation is independent of the isoform
if the HSPG-bound isoforms are protected against degra-
dation. Conversely, degradation is isoform-specific when
the heavier isoforms can be degraded when bound to
H S P G sa sw e l la si ns o l u t i o n .The heavier isoforms will
be degraded more due to their longer residence time.
Concentrations of Receptors and HSPG
Concentrations of VEGF, abluminal VEGF receptors,
and ECM HSPG were estimated previously [8,42,60,67]
(see Table 4). VEGF levels were taken to be V0 =1p M
as previously determined from the literature [67]. We
assume that each endothelial cell has a fixed population
of VEGFR maintained by a balance of receptor insertion
into the plasma membrane and internalization. We
assumed a base condition of [R1]Total =1 0
4 and [R2]Total
=1 0
4 per vascular surface corresponding to the area of
a tip cell (515 μm
2). To account for the excess of NRP1,
we use [N1]Total =3 · 1 0
4 molecules/515 μm
2.T h eb i n d -
ing site density of HSPG in the ECM was 750 nM [41].
Definition of Gradient Metrics for VEGF isoforms and
VEGF receptors
Endothelial cells may sense absolute or relative gradients
of VEGF [68,69]. For initiation of vascular sprouting, the
gradient across one cell is likely to be sensed. For sprout
extension and maintenance of the tip cell/stalk cell dif-
ferentiation, the signaling difference between two cells
(e.g. a tip and stalk cell [70]) may be more relevant.
In the present study we consider gradients only
between the front and back of the surface of the tip cell,
with mean concentrations ([V]Tip) defined over the tip
cell’s entire surface. The absolute gradient, denoted by
AGV or ΔTip[V] is the difference in VEGF concentration
between the tip cell front and back. Note that the abso-
lute gradient is additive over all isoforms, e.g. AGV =
AG165 +A G 121 for a two isoform distribution. The
steepness of the VEGF distribution (relative gradient) is
the absolute gradient normalized to either the mean tip
t o t a ls o l u b l eV E G F ,i . e .f r a c t i o n a lg r a d i e n to rF G 165,o r
to the mean tip concentration of the isoform under con-
sideration, e.g. IFG165:
IFG165 =
AG165
[V165]Tip
=
1
[V165]Tip
 Tip[V165] ≈  Tip ln[V165]
(24)
FG165 =
AG165
[V165]Tip +[ V 121]Tip
=
1
[V165]Tip +[ V 121]Tip
 Tip[V165]
(25)
Note that the above metrics differ only in the presence
of multiple VEGF isoforms.
Table 4 Model Conditions
Parameter Symbol Value Ref.
Initial mean VEGF level V0 1 pM [67]
VEGF gradient over domain g0 5%/40 μm Assumed
[HSPG] in ECM [H] Total 0.75 ·10
-6 mol/L [41]
System with receptors
Total VEGFR2 levels per area of tip cell on vasculature [R2]Total 10,000/(area of tip cell); area of tip cell = 515 μm
2 [42]
Total VEGFR1 levels per area of tip cell on vasculature [R1]Total 10,000/(area of tip cell) Assumed
Total NRP1 levels per area of tip cell on vasculature [N1]Total 30,000/(area of tip cell) Assumed
VEGF (typically VEGF165) secretion rate q 5.27·10
-5 molec/μm
2 ·s Calculated
VEGF clearance rate kclear 0.0399 μm/s Calculated
System without receptors
VEGF (typically VEGF165) secretion rate q 4.39·10
-5 molec/μm
2·s Calculated
VEGF clearance rate kclear 0.0948 μm/s Calculated
HSPG gradient (Figure 4B)
HSPG gradient gH0 30%/40 μm Assumed
Soluble VEGF degradation (Figure 4C)
Degradation rate of soluble VEGF kdeg
V 0.001 s
-1 Assumed
Degradation rate of matrix-bound VEGF kdeg
VH 0s
-1 Assumed
Matrix-sequestered VEGF degradation scheme (Figure 4D)
Degradation rate of soluble VEGF kdeg
V 0.001 s
-1 Assumed
Degradation rate of matrix-bound VEGF kdeg
VH 0.001 s
-1 Assumed
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surface VEGF-bound receptor complexes. In this case,
the gradient is limited to the axial (z) direction due to
rotational symmetry in our model. We normalize the
absolute gradient of receptor complexes to the total
amount of a particular receptor, e.g.:
AG165-R2 =
1
[R2]Total, Tip
 Tip[V165R2] (26)
where [R2]Total, Tip is the sum of all forms of VEGFR2 on
the tip cell surface. Using the fractional occupancy (FO) of
a VEGF isoform to a VEGF receptor, the fractional gradi-
ent of VEGF165 bound to VEGFR2 in a system consisting
of isoforms VEGF121 and VEGF165 can be expressed as:
FG165-R2 =
1
[V165R2]Tip +[ V 121R2]Tip
 Tip[V165R2]
=
AG165 - R2
FO165−R2 + FO121−R2
(27)
We introduce the concept of sensitivity, S, to define
the multiplicative relation between a metric in VEGFR2
binding and a similar metric in the VEGF distribution,
e.g. SIFG-165 =I F G 165-R2/IFG165.N o t et h a tS IFG also
describes the factor increase in the fractional occupancy
(FO) given a factor increase in [VEGF], strictly valid
only in the differential limit:
SIFG-165 =

1
[V165R2]
d[V165R2]
dz

·

1
[V165]
d[V165]
dz
−1
=

d[V165R2]
[V165R2]

·

d[V165]
[V165]
−1
=
d ln(FO)
d ln[V165]
(28)
For a single receptor detecting a single ligand, SIFG is
always less than 1 (SIFG = 1 - FO) (for more detail, see
Additional file 1, section S2.2).
Additional Assumptions
We assume that degradation and proteolysis is uni-
formly distributed. Our model does not also fully reflect
the contribution of vasculature to VEGF transport.
While vasculature-mediated internalization is thought to
represent the primary clearance for VEGF in tissue [43],
our model only implicitly represents such effects
(through a clearance at z = -L), neglecting isoform-spe-
cific variation. We also assume constant internalization
and insertion rates for the VEGF receptors, resulting in
constant total receptor population on the sprout. This is
justified because we are primarily interested in the sen-
sory role of the sprout and not in its internalization
capacity, however ligand-induced shifts in NRP1 and
VEGFR2 may also alter sensory function. Mechanistic
models of these processes have not been developed and
thus we did not incorporate them in the current study.
Results
The computational model predicts that the steady-state
distribution of soluble VEGF is isoform-independent when
considering only diffusion and matrix binding
When VEGF is secreted, extracellular HSPGs are pre-
dicted not to influence the distribution of the soluble
fraction of VEGF (Figure 3A vs. 3B); nor do they influ-
ence receptor signaling (Figure 3, bar graphs), assuming
VEGF-HSPG complexes in the ECM cannot directly
ligate VEGF receptors. At steady state, each molecule of
VEGF that binds to the matrix is matched by a molecule
that unbinds. Note that using physiological parameters,
VEGF concentration is significantly below the Kd for
matrix binding ([V] ~ 1 pM, Kd =1 6 5n M )r e s u l t i n gi n
HSPG binding sites remaining unsaturated; in this
regime, matrix-bound VEGF concentration is linearly
proportional to soluble (unbound) VEGF concentration
at all spatial positions.
At the tip cell, the absolute gradient of unbound
VEGF is ~0.059 pM/40 μm. The direction of the gradi-
ent of receptor signaling (characterized in this study by
the receptor occupancy) is the same, with magnitude
~30 VEGF-VEGFR2/40 μm. The relative steepness (iso-
form fractional gradient, IFG) of both the VEGF and
VEGF-VEGFR2 distributions are similar, IFGVEGF =
6.39%/40 μm and IFGVEGF-VEGFR2 = 6.12%/40 μm. Thus,
the sensitivity of VEGFR2 binding to VEGF gradients
(SIFG) is high (Figure 3B). Note that VEGF receptors
also locally deplete VEGF and thereby influence the dif-
fusion of VEGF (Figure 3, arrowed dotted lines); in the
case shown, receptors capture ~39% of the secreted
VEGF.
Differences in VEGF gradients can arise from differences
in VEGF degradation
The lack of influence of HSPGs on VEGF gradients at
steady state suggests that different isoforms secreted at the
same rate (as occurs in transgenic systems designed to
express only one isoform), and differing only in HSPG
binding, will have similar soluble VEGF distributions
(Figure 4Aii). Matrix-bound VEGF increases with HSPG
affinity of the isoform (Figure 4Aiii), as does the total
amount of extracellular VEGF (for VEGF121: 646 mole-
cules; VEGF165: 3.58·10
3 molecules; VEGF189: 5.76·10
4
molecules). However, because bound VEGF is propor-
tional to soluble VEGF, the relative gradients of matrix-
bound VEGF are the same for each isoform. Over the
simulated length scales, total VEGF concentration gradi-
ents of different isoforms would not intersect (Figure
4Aiv), regardless of HSPG concentration (not shown).
Thus, differential HSPG binding of isoforms is not suffi-
cient to account for observed VEGF patterning in vivo
(Figure 1A).
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could cause the observed gradients, but this scenario also
did not lead to isoform-specific differences in soluble
VEGF; however, it did lead to larger isoforms having
steeper distributions in bound and total VEGF (Figure
4Biv). Still, VEGF levels between different isoforms are
not predicted to intersect within the spatial frame of
reference.
We first considered whether the steady-state assump-
tion was accurate, since transient diffusion of isoforms
having different HSPG affinities can momentarily lead
to differential isoform patterning. However, experimen-
tal evidence points to VEGF121 and VEGF165 having
rapid kinetics in vivo (τ ~ 1 h) [51,71], which likely indi-
cates that VEGF patterning operates close to steady
state. We will consider the ability of VEGF-cleaving pro-
teases to create these spatial distributions; however, it is
of note that VEGF fragments have not yet been
observed in developing tissues [17].
N e x t ,w ec o n s i d e r e dV E G Fd e g r a d a t i o n( F i g u r e4 C , D ) .
In vivo, VEGF diffuses in an environment filled with
cells, which may selectively uptake VEGF isoforms, e.g.
through cell surface receptors, possibly in conjunction
with NRP1 or cell-surface HS [72]: these effects are
incorporated into the VEGF degradation term of our
model. Degradation may also result from VEGF inactiva-
tion by isoform-selective VEGF inhibitors, e.g. connective
tissue growth factor, sVEGFR1, thrombospondin-1, or by
proteases that can cleave VEGF to fragments that are not
recognized by commonly employed antibodies.
As described in the methods section, we considered
two specific cases for degradation: first, the “soluble
VEGF degradation model” in which HSPG-bound VEGF
is protected from degradation (Figure 4C); and the
“matrix-sequestered VEGF degradation” model, in which
HSPG-bound VEGF can be degraded (Figure 4D). The
former is similar to heparin-bound bFGF being pro-
tected against plasmin cleavage [73].
Figure 4 Mechanisms of forming differential isoform gradients. We consider the distributions of VEGF121,V E G F 165, and VEGF189 under four
scenarios that may be responsible for isoform patterning in vivo (i, soluble fraction; ii, bound fraction; iii, soluble + bound VEGF). A, reversible
HSPG binding considered previously in Figure 3 (HSPG-binding-only model). B, patterning of the underlying HSPG ([H]Total = 750 nM at z = 0,
30%/40 μm). C, soluble VEGF degradation; this is isoform-independent degradation (all isoforms are degraded at the same rate), but HSPG-
bound VEGF is protected from degradation; kdeg =1 0
-3 s
-1. D, matrix-sequestered VEGF degradation; all isoforms are degraded, and HSPG
binding confers no protection; this has the effect of increasing degradation of HSPG-binding isoforms due to their longer residence time, even
though all isoforms have the same degradation rate constant kdeg =1 0
-3 s
-1.
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protect VEGF (Figure 4C), the soluble VEGF distribu-
tion is independent of HSPG binding, as if the HSPGs
were not even present. The relative gradients of the
VEGF isoforms are equal (8.4%/tip length) and thus can-
not recapitulate isoform-dependent localization. In addi-
tion, total VEGF in the system is approximately
proportional to the HSPG binding affinity.
In contrast, when HSPG-bound VEGF is vulnerable to
degradation (Figure 4D), the different grading of VEGF
isoforms seen in vivo (e.g. Figure 1A) is recapitulated
[7,21,22,39]. Specifically, the strongly heparin-binding
VEGF189 produces a very steep distribution (Figure 4Div).
As a consequence of this, close to the source of secretion,
increased ECM-binding affinity (i.e. longer isoform) corre-
sponds to increased levels of bound VEGF; but at suffi-
ciently far distances, this trend is reversed and the highly
diffusible isoform is more abundant (Figure 4Diii). Despite
different spatial localization, the total amount of VEGF in
the system is similar for each isoform (for VEGF121: 229
molecules; VEGF165: 345 molecules; VEGF189: 379 mole-
cules), and may be consistent with data from [7,22].
Proteolytic cleavage of bound VEGF increases soluble
VEGF only in a model of isoform-specific degradation
VEGF cleavage (generating sizeable fragments) is also an
important modulator of vascular patterning and experi-
mentally, increased cleavage seems to mimic the effects of
reduced HSPG binding affinity: increase in soluble VEGF,
increase in range of the VEGF signal with a simultaneous
decrease in the magnitude of the VEGF gradient, decrease
in matrix-bound VEGF, and possibly, preservation of the
total tissue VEGF levels [7,12,13,17,19,21]. Here we con-
sider the role of VEGF-cleaving proteases on the VEGF
distribution of the different isoforms for two different sce-
narios: the HSPG-binding-only model, which provides a
reference case (Figure 5) and the model including matrix-
sequestered VEGF degradation (Figure 6), which we saw
above can result in VEGF isoform gradients similar to
those observed experimentally. We assume VEGF cleavage
can act on both soluble and matrix-bound VEGF.
Surprisingly, inclusion of proteolytic cleavage did not
affect total soluble VEGF levels in the HSPG-binding-
only model, despite reducing levels of uncleaved (full-
length) VEGF and producing VEGF114, a non-HSPG
binding diffusible isoform (Figure 5Ci,Di,Ei,). Mathema-
tical analysis indicates that this effect is similar to the
HSPG binding independence noted earlier. Proteases are
predicted to reduce matrix-bound VEGF levels (Figure
5Dii,Eii), due to a proportional decrease in uncleaved
VEGF, which is accompanied by a significant steepening
of these distributions (fractional gradients are noted
next to the lines on Figure 5). Comparing the different
VEGF isoforms, proteases cleave VEGF189 much more
thoroughly than VEGF165, while total VEGF in the
VEGF121 system (Figure 5Cii) is not affected by proteo-
lysis because its cleavage produces an equivalent iso-
form. This potentiation of VEGF proteolytic cleavage by
HSPG binding is due to increased residence time of the
matrix-binding isoforms.
In contrast, with the inclusion of matrix-sequestered
VEGF degradation (Figure 6), proteolytic release of
VEGF resulted in increased soluble VEGF levels, size of
this increase was proportional to the matrix affinity of
the uncleaved isoform (Figure 6Ci,Di,Ei). Furthermore,
both the soluble VEGF and total VEGF distributions
have reduced gradients (Figure 5Hi,ii) indicating that
VEGF gradients can be disrupted by proteases in this
model. Matrix-bound VEGF decreased due to the action
of protease; however, its decrease was not as significant
as in the HSPG-binding-only model, due to the exis-
tence of VEGF degradation processes. Overall, the total
VEGF amount in each tissue is well preserved by the
action of proteases (in the presence of proteases,
VEGF121 system: 229 molecules; VEGF165 system: 380
molecules; VEGF189 system: 428 molecules; compare to
Figure 4D levels; refer to Figure S3.1).
We note that in each case, cleaved VEGF has a nearly
flat concentration profile, a consequence of it not being
secreted at a single location. This contrasts with the
uncleaved soluble and bound fractions, which are pro-
portional to each other and are sharpened by proteases.
Another surprising finding is that in the presence of iso-
form-specific degradation, the concentration of cleaved
VEGF is similar in each isoform system (Figure 6Ci,Di,
Ei). As described in more detail in Additional file 1, sec-
tion S2, this is a result of total VEGF being preserved,
indicating that the residence time of each isoform, and
hence the time available for cleavage to occur, is similar.
Correlating VEGF patterning to vascular patterning
suggests total soluble VEGF may be an optimal VEGF
signal
Using the VEGF patterning in vivo as recapitulated in the
model, we now ask whether there is a viable VEGF-based
guidance cue for cell sensing that is consistent with the
twin observed properties: monotonic increase in vascular
density with isoform length; and the opposite effect of
VEGF cleavage (Figure 7A). We present results for VEGF
near the tip cell (z = -40 to 0 μm), with an extended
range of VEGF isoforms and MMP activity levels to com-
pare, side-by-side, the isoform dependence and the
MMP-based proteolytic dependence (Figure 7B,C).
In the HSPG-binding-only model (Figure 7B), total
soluble VEGF is constant, and thus is unlikely to carry
relevant information regarding vessel patterning. Instead,
such information could come from changes in: soluble
uncleaved VEGF; cleaved VEGF; or matrix-bound
Vempati et al. BMC Systems Biology 2011, 5:59
http://www.biomedcentral.com/1752-0509/5/59
Page 13 of 24VEGF. In order for a signal to recapitulate the isoform
and MMP dependence shown in Figure 1B, it should
behave in the same fashion to decreasing HSPG affinity
as it does to increasing MMP activity. In the context of
Figure 7, that means that the behavior moving to the
right along the x-axis should be the same on the HSPG
and MMP graphs. Here however, levels of soluble
uncleaved VEGF increase monotonically as the HSPG
affinity of the secreted isoform decreases (due to
decreased residence time in the ECM), but decrease as
MMP activity increases. Cleaved VEGF (Figure 6B, red
lines) is also inconsistent. Matrix-bound VEGF, however,
has a biphasic behavior; at the tip cell, isoforms with
intermediate and lower affinity to HSPGs satisfy the
requirement that MMP effects oppose HSPG binding
effects, but above an affinity limit this is violated (Figure
6B, yellow shaded region). This biphasic effect arises
because greater matrix binding affinity results in greater
accumulation close to the source of secretion, but also
more rapid deterioration of the signal in space caused
Figure 5 Effect of VEGF-cleaving MMPs on the VEGF distribution. Proteases (MMPs) were added to the HSPG-binding-only system at kP =
2.8·10
-4 s
-1 for systems expressing VEGF121 (C), VEGF165 (D), or VEGF189 (E). We look at the components of the soluble VEGF distribution (i), and
bound and total VEGF (ii), both before the addition of proteases (solid lines), and after (dashed lines). The total VEGF distributions of different
isoforms, in the presence of proteases, are displayed against each other (B). Simulations were performed in the absence of receptors (parameters
given in Table 4). Isoform fractional gradient values at the tip cell are noted in grey with units %/40 μm.
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Page 14 of 24by proteolysis over a longer residence time. This effect
was also seen in Figure 5B, as total VEGF189 levels fall
below those of VEGF165 at the tip cell. Note that the
closer the tip cell is to the source, the greater the likeli-
hood that the monotonic behavior between isoforms is
maintained, indicating that the distance from the VEGF
source, all other factors being equal, may be a major
determinant of isoform-specific vascular patterning.
In the matrix-sequestered VEGF degradation model
(Figure 7C), soluble uncleaved VEGF, cleaved VEGF, and
matrix-bound VEGF follow similar behavior as in the
above HSPG-binding-only model. However, total soluble
V E G Fi sn o tc o n s t a n ti nt h i sm odel. Interestingly, while
neither soluble uncleaved nor cleaved VEGF are individu-
ally viable guidance cues, their sum (total soluble VEGF),
displays the desired behavior, increasing with decreased
isoform affinity to the matrix and with increased MMP
activity, though at sufficiently high affinities, the differ-
ences at HSPG affinities larger than that of VEGF165 are
not large. In addition, this behavior is present over the
entire range of parameters, indicating that it is robust in
its ability reproduce vascular patterning.
Figure 6 Effect of VEGF-cleaving MMPs on the VEGF distribution. Proteases (MMPs) were added to the matrix-sequestered VEGF
degradation system at kP = 2.8·10
-4 s
-1 for systems expressing VEGF121 (C), VEGF165 (D), or VEGF189 (E). We look at the components of the soluble
VEGF distribution (i), and bound and total VEGF (ii), both before the addition of proteases (solid lines), and after (dashed lines). The total VEGF
distributions of different isoforms, in the presence of proteases (B, black lines), are compared to those in the absence of protease (B, grey lines).
Simulations were performed in the absence of receptors (parameters given in Table 4). Isoform fractional gradient values at the tip cell are noted
in grey with units %/40 μm.
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Page 15 of 24Figure 7 Competing influences of HSPG binding and VEGF cleavage on biological responses. Experimental evidence indicates that HSPG
binding and VEGF cleavage modulate the same axis of vascular phenotypes (A) [6,7,13,17]. To understand how the VEGF distribution may be
responsible for vessel patterning, we measured various metrics of the VEGF distribution as they would vary either with variation in the HSPG
affinity of the secreted isoform (with MMP activity held constant at kP = 2.8·10
-4 s
-1, dash-dotted lines) or with variation in the background
proteolytic activity (kP ranged from 10
-6 s
-1 and 10
-2 s
-1, assuming that VEGF165 is secreted). The HSPG-binding-only model (B) and the matrix-
sequestered VEGF degradation model (C) were considered. Circle markers indicate respective positions of (from left to right) VEGF189, VEGF165,
and VEGF121 (Kd = ∞). Control cases simulated in the absence of MMPs are given in solid lines. Yellow boxes in B and C indicate the range
where bound VEGF does not display behavior consistent with the experimental data. Simulations were performed in the absence of receptors,
the presence of which would have a negligible impact on the VEGF distribution, to obtain computational efficiency permitting simulation of a
broad range of parameters (parameters given in Table 4).
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uncleaved VEGF (i.e. soluble uncleaved VEGF + matrix-
bound VEGF) (not shown), display similar biphasic beha-
v i o r sa sd o e sm a t r i x - b o u n dV E G Fa n dt h u sd on o t
enhance the signal provided by the matrix-bound form.
The model also predicts the magnitude of VEGF gradi-
ents present near the tip cell. While fractional gradients
appear to be significantly poorer candidates for guidance
cues than are VEGF concentrations, absolute gradients
seem to be as effective as VEGF concentrations (Addi-
tional file 1, section S3; Figs. S3.2, S3.3). Absolute gradi-
ents greatly extend the range of isoforms for which
matrix-bound VEGF in the HSPG-binding-only model
displays isoform monotonicity (Additional file 1, Figure
S3.2Biii), however in the matrix-sequestered VEGF
degradation model, it seems to show little variation with
respect to changes in MMP activity, indicating weak
HSPG/MMP antagonism (Additional file 1, Figure S3.3).
Effects of receptor binding on isoform monotonicity and
HSPG/MMP antagonism
Endothelial cells respond not to VEGF gradients directly
but to VEGF receptor activation. Can VEGF receptors
accurately sense total soluble VEGF, which we identified
as a potential cue, or do other extracellular signals
b e c o m er e l e v a n t ?N o t et h a ti nt h ea b s e n c eo fN R P 1
expression, VEGFR2 and VEGFR1 binding will be simi-
lar to the soluble distributions given in Figure 7, because
uncleaved and cleaved VEGF isoforms bind similarly to
the VEGF receptors. The presence of NRP1 may com-
pensate for the inability of longer isoforms to diffuse far
in tissues.
We imposed the VEGF distributions calculated in Fig-
ure 7 onto our model of VEGF receptor interactions
(refer to Additional file 1, section S4.1). VEGFR2 binding
was similar for the matrix-sequestered VEGF degrada-
tion model (Figure 8) and the HSPG-binding-only
model (not shown). VEGFR2 binding shows greatest
binding at isoform affinities between VEGF121 and
VEGF165, violating isoform monotonicity (Figure 8Ai), a
result of the isoform-specific potentiation of the under-
lying uncleaved VEGF by NRP1. At high enough matrix
affinities this is, however, unable to compensate for the
low levels of uncleaved VEGF seen for these isoforms.
We note that uncleaved VEGF189 (and possibly other
long isoforms) cannot bind VEGFR2 [46], though its
cleavage product can; this does not significantly alter
the shape of the curve (Figure 8Ai), as most VEGF189 is
cleaved (Figure 7C)
We note that when the uncleaved isoform exhibits
strong HSPG binding, total soluble VEGF is due primar-
ily to cleaved VEGF, and when the uncleaved isoform
has minimal ECM binding, then cleaved VEGF is not
significant (Figure 7C). A similar feature was noted in
VEGFR1 binding in the presence of NRP1 (Figure
S4.1A). As a result, we also tested the potential role of
VEGFR1 signaling in recapitulating total soluble VEGF
signaling (Figure 8B). Total VEGFR1 binding displays a
greater range of isoform monotonic behavior than
VEGFR2 binding, however, it is limited only up to the
VEGF165 isoform, beyond which VEGFR1 binding
remains flat or may actually increase with increased
matrix-binding affinity (refer to Additional file 1, Figure
S3.3Dii).
Discussion
Our study proposes an important reinterpretation of the
role of HSPGs and VEGF-cleaving proteases in the con-
trol of VEGF patterning in vivo. Our central proposition
is that differential isoform degradation (or clearance),
and not a difference in diffusion arising from HSPG
binding, controls the spatial localization of VEGF in tis-
sues (Figure 9A).
In the developing hindbrain system, VEGF120 distri-
butes in a much more disperse manner (Figure 1A) than
VEGF164 [13]. We find that while VEGF164 may diffuse
slower in tissues than VEGF120, differences in grading
will only arise when VEGF164 is also degraded more
rapidly by the surrounding hindbrain parenchyma, possi-
bly due to specific uptake by cell surface HSPGs or
NRP1, preventing it from diffusing far (Figure 9A). We
propose that this difference in degradation rates between
isoforms (which we term isoform-specific degradation,
and is here a result of degradation of matrix-bound
VEGF) also explains why secretion of non-heparin bind-
i n gi s o f o r m ss u c ha sV E G F 113 or VEGF120 leads to
greater VEGF levels in the solution phase of tissues than
secretion of heavier isoforms, given identical secretion
rates [7,21]. Note that assuming a simpler mechanism of
reversible HSPG binding in an in vivo system is not able
to explain this behavior at steady state (Figure 4A).
Importantly, our mechanism of isoform-specific degrada-
tion also provides a general explanation for the phenom-
ena of protease-mediated redistribution of VEGF activity:
proteases, by either cleaving VEGF [7], cleaving HSPGs
[15], or by cleaving VEGF inhibitors [32], inhibit the
degradation of VEGF (Figure 9A), thereby leading to the
accumulation of VEGF in tissues and an increased range
of receptor activation on the vasculature. This hypothesis
is distinct from what is commonly noted in the literature
as VEGF release, in which VEGF is focally released from
the matrix by the action of proteases and diffuses to acti-
vate vasculature.
The second thrust of our current work is the elucida-
tion of how VEGF isoforms and VEGF-releasing pro-
teases might regulate vascular morphology (Figure 1B).
We originally asked the question: which VEGF metrics
may be responsible for guiding vascular patterning, to
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Page 17 of 24recapitulate both isoform monotonicity [6,12,13,25] and
the protease dependence in vascular patterning [6,7]?
We identified several possibilities including the levels of
matrix-bound VEGF, soluble VEGF levels, NRP1 depen-
dent signaling, and even VEGF gradient directionality.
Using the results of our model, we can now provide a
more specific answer to this question.
For example, the model predicts as expected that
VEGF188-secreting tumors would have the greatest levels
of peritumoral matrix-bound VEGF [6], however, farther
away at the vascular front, matrix-bound VEGF levels
m a ya c t u a l l yb el o w e rt h a ni fV E G F 165 were being
secreted (Figure 9B). Thus, how a sprout experiences
the ordering of the isoforms by sensing matrix-bound
VEGF may not always be monotonic with respect to the
heparin binding affinity of the VEGF isoform; it will be
dependent on the distance between the sprout and the
VEGF source (Figure 9B). (Note that the specific order-
ing depends on HSPG concentrations, protease levels,
degradation rates, etc. Given their intrinsic variability in
biological systems, the conclusion that a sufficiently
strong matrix-binding isoform will have less matrix-
bound VEGF is robust.) Instead, the possibility that
VEGF189-secreting systems also have the lowest levels of
soluble VEGF of the different isoform-expressing sys-
tems seems to be consistent, even in the presence of
proteases (Figure 9B).
An important alternative to the concentration of
matrix-bound VEGF levels may however be its direction-
ality, especially as VEGF189 seems to have the sharpest
distributions in the absence of proteases (Figure 4Diii).
While this holds true in the absence of proteases and can
possibly explain observations in the mouse hindbrain
[13], this metric does not account for the effect of VEGF-
Figure 8 VEGFR2 and VEGFR1 signaling in mediating vascular phenotypes. Using the VEGF distributions calculated by the isoform-specific
degradation model in Figure 7 we calculated VEGF binding to VEGFR2 (A) and VEGFR1 (B). We assume 10
4 VEGFR2, 10
4 VEGFR1, and 3*10
4 NRP1
per tip cell (assuming no VEGF depletion by the sprout). VEGF isoforms show isoform-specific differences in their ability to bind NRP1 and the
VEGFR1-NRP1 complex. To calculate the receptor binding parameters for arbitrary isoforms, we imposed two constraints to interpolate/
extrapolate around the known VEGF isoforms (refer to Methods, Kinetic Parameters). VEGF/NRP1 affinity was made to recapitulate the lack of
binding of VEGF121 and stronger binding affinity of VEGF189 [37]. VEGF binding affinity to the VEGFR1-NRP1 complex and NRP1 coupling to the
VEGF-VEGFR1 complex was set such that VEGF121 can fully bind to VEGFR1-NRP1 [95], while any isoform with greater HSPG affinity than that of
VEGF165 cannot bind. Circle markers indicate (from left to right) VEGF189, VEGF165, and VEGF121 (Kd = ∞).
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tion, instead of behaving in a HSPG-antagonistic fashion
(Figure S4.3A). VEGF189 a l s om a yh a v es t r o n g e rN R P 1
binding than VEGF165 [37], however our results show
that soluble uncleaved VEGF189 levels may be so low (the
majority will be cleaved or degraded), that total NRP1-
potentiated VEGFR2 signaling may be weaker than that
in VEGF165-secreting systems. In fact, our model shows a
surprising result: VEGFR1 binding of total soluble VEGF
seems to better reconcile both isoform monotonicity and
the antagonistic relationship between HSPG affinity and
MMP activity than VEGFR2 binding does (Figure 9).
Our results may provide insight into the nature of sev-
eral experimental observations regarding vascular pat-
terning. A comparison of our results to those of
Ruhrberg et al’s hindbrain data suggest that while the
overall VEGF distribution is spatially non-monotonic
(Figure 1A) [13], the underlying soluble fraction of
VEGF is monotonic and is the basis for endothelial
behavior. We note, however, that several important bio-
logical effects need to first be taken into account, for
example the roles of filopodia [12,13,74] and the direct
receptor signaling of matrix-bound VEGF [35].
The loss of monotonicity for matrix-bound VEGF
(Figure 7B, Figure 9B) is a result of the isoform-depen-
dent decrease of the soluble uncleaved VEGF fraction in
space. We now discuss how the tip cell filopodia can
contribute to the process of isoform sensing. By project-
ing out in front of the tip cell, filopodia may be able to
detect a region of space where matrix-bound VEGF may
in fact operate in an isoform-monotonic manner (Figure
9B), effectively increasing the spatial range of the
matrix-bound VEGF fraction’s isoform monotonicity.
We conceptualize this to sprouting angiogenesis. In the
initial stages of sprouting where the sprout is far away
from the VEGF source, only soluble VEGF will exhibit
isoform monotonicity. However, as a sprout continues
to invade closer into the VEGF secreting tissue, matrix-
bound VEGF signaling and VEGF gradients will also
exhibit the correct isoform monotonicity (refer to Addi-
tional file 1, section S3.2, Figure S4.4). These effects
would be relevant in vivo as VEGF gradients never seem
to be more than 50 μm in front of the vascular front
[12,13], a range that can easily be sensed by filopodia
[12]. Thus, while total soluble VEGF is theoretically the
most isoform-monotonic signal, there may be no practi-
cal differences between it and matrix-bound VEGF. In
fact, the information provided in matrix-bound VEGF
may be even more relevant than that of soluble VEGF
as it can result in differential VEGFR2 signaling that
favors activation of p38/MAPK compared to soluble
VEGF [35] and may mediate increased interaction with
cell-surface NRP1 [34], both of which may play a direct
role in branching and migration behaviors leading to
increased vascular density. Unlike the behavior of
matrix-bound VEGF, an isoform monotonic signal in
NRP1-mediated VEGFR2 signaling does not necessarily
emerge as a sprout invades into the VEGF secreting tis-
sue (a result of reaction limitations in VEGF/VEGFR2/
NRP1 coupling) (Figure S4.4C), indicating that NRP1-
mediated VEGFR2 signaling may be less capable of giv-
ing rise to isoform-specific increases in vascular branch-
ing complexity. However, this conclusion is based on
assuming a model where receptors only bind soluble
VEGF; how the signaling of matrix-bound VEGF
changes these conclusions is not known.
Figure 9 Summary of VEGF transport results. A, We propose that isoform-specific patterning in tissues results from differences in their rates
of degradation (i.e. isoform-specific degradation), potentially mediated by HSPG or NRP1 binding. For longer isoforms to have more localized
VEGF distributions [13], their degradation must be more rapid. We hypothesize that proteases enhance the spatial propagation of VEGF (i.e. VEGF
redistribution) [16,17,19] by inhibiting this isoform-specific VEGF degradation. B, Role of matrix-binding affinity on VEGF patterning. Our
computational model shows that HSPG-binding affinity affects soluble and matrix-bound VEGF in different manners. Increased matrix binding
affinity universally decreases total soluble VEGF, in the case of HSPG-mediated isoform-specific degradation. However, matrix-bound VEGF shows
increased “localization”, a result of two competing behaviors: an increase in concentration due to accumulation close to the source of secretion,
and a decrease in concentration farther away due to an increased rate of degradation. This causes matrix-bound VEGF to lose its isoform-
monotonic behavior. The ordering of how isoforms are perceived is dependent upon the distance that sensing occurs from the VEGF source.
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V E G Fm a yb ea b l et oa l s om e d i a t ei s o f o r m - s p e c i f i cd i f -
ferences in vascular patterning. However, this conclusion
is at odds with the VEGFR2-dependent nature of angio-
genesis in the retina [12], in in vitro patterning of porcine
aortic endothelial cells [7], and in MMP9 induced carci-
nogenesis [16]. In addition, VEGFR1 signaling supports
migratory behavior through p38/MAPK [26], however
our results suggest an inhibitory role of VEGFR1 signal-
ing on vascular density (Figure 8Bi). While our model
cannot elucidate the importance of VEGFR1 signaling, it
is interesting to note that when VEGFR2 signaling is
monotonically increasing with the isoform length,
VEGFR1 signaling is decreasing, suggesting that a bal-
ance between the two receptors may be important.
The unique role of matrix-bound VEGF in mediating
the branching phenotype through filopodia may offer an
interesting solution to the paradoxes of VEGF-cleaving
MMPs in tumor growth. For example, both VEGF188
tumors and VEGF164Δ108-118 tumors are similar in that
they have higher intratumoral vascular density and
lower-diameter vessels compared to VEGF164 tumors;
however, whereas VEGF164Δ108-118 tumors are markedly
more proliferative than VEGF164 tumors [7], VEGF188
tumors show negligible growth [6]. We may conclude
that this discrepancy indicates that the resulting vascular
beds in the two tumors are different in ways that the
intratumoral vessel density cannot measure, for example,
in their connectivity to peritumoral vasculature [6],
which may be a limiting factor for nutrient delivery; we
propose that a separate aspect of VEGF signaling con-
t r o l st h i sl a t t e rb e h a v i o r .Our model suggests a crucial
difference between the two tumors: while VEGF188
tumors show minimal VEGFR2 activation, even less
than that of VEGF120 tumors, VEGF164Δ108-118 tumors
instead show even higher VEGFR2 activation than
VEGF164 tumors (Figure 8A). As a result, it may be pos-
sible that the ability of the vasculature to support tissue
growth may be dictated by VEGFR2 activation at the
vessel itself, due to the receptor binding behavior of
soluble VEGF, as suggested in numerous studies [16,17].
Furthermore, notice that peak VEGFR2 activation
occurs between the VEGF165 and VEGF121 isoforms
(Figure 8Ai). This may support the observation that
VEGF120 is at least as tumorigenic as VEGF164 in some
systems due to intrinsic differences between systems
[25,39]. Overall, we hypothesize that intratumoral vessel
density and branching is determined by matrix-bound
VEGF detected by filopodia removed from the vessel
surface, while vessel efficacy is dictated by VEGFR2 acti-
vation at the vessel body. As a result, we thus posit that
the tumorigenic behavior ultimately depends on the
ability of VEGF to keep its receptor and NRP1 binding
domains intact. The inability of VEGF188 tumors to elicit
VEGFR2 activation, despite it potentially having higher
affinity to NRP1 than VEGF164, is a result of its degrada-
tion and cleavage (Figure 7C).
This hypothesis may also explain the paradoxical roles
of specific proteases in tumorigenesis. Our mechanism of
MMP-mediated VEGF redistribution (Figure 9A) shows
that proteases will increase the functional soluble VEGF
concentration by inhibiting the process of VEGF degra-
dation. However, while several modes of VEGF redistri-
bution, such as through MMP9, heparinases, or VEGF
inhibitor cleavage are implicated as pro-tumorigenic,
mediating an angiogenic switch [15,16,19,20,29,30,32],
there are several notable exceptions where protease activ-
ity instead leads to diminished tumor growth [7], an
effect similar to the plasmin-mediated loss of wound
healing due to a loss of angiogenesis [75]. We note an
important trend: in studies where pro-tumorigenic beha-
vior occurs from VEGF release, VEGF has not been
shown to be directly cleaved. Bergers et al have shown
that MMP9 mediates VEGF-release induced carcinogen-
esis in pancreatic islets [16] without determining the
mechanism of release. However, subsequent studies have
shown that MMP9 does not necessarily cleave VEGF
[15,31-33], as suggested by [7], but instead acts to cleave
HSPGs directly [15]. In fact, Joyce et al [30] show that
MMPs and heparinases have similar effects in the pan-
creatic islet system, which strengthens the argument that
the MMP9 induced angiogenic switch in [16] may have
been mediated by HSPG cleavage. In contrast, studies
where proteases reduce the angiogenic potential of VEGF
show direct evidence of VEGF being cleaved and/or
degraded [7,75,76]. We propose that VEGF needs to
maintain coreceptor domains for effective tumorigenesis.
Cleavage of VEGF, while increasing the total soluble
VEGF concentration, may decrease overall VEGFR2 acti-
vation due to a loss of NRP1 binding (recapitulated in
Figure 8Aii); heparinases, MMP9, and VEGF inhibitor
proteases also prevent VEGF degradation but redistribute
intact, coreceptor-binding VEGF.
Our results suggest that a central facet of VEGF pat-
terning in vivo is its degradation, which we show neces-
sarily occurs in an isoform-specific manner. Several
mechanisms may underlie VEGF’s isoform-specific
degradation, and it is not currently known what, if any,
mechanisms operate in the different in vivo experimen-
tal systems used. Interstitial cells and endothelial cells
from nearby vessels may uptake VEGF isoform in an
HSPG- or NRP1- dependent manner. This is supported
by observations that NRP1 and VEGF receptors are typi-
cally present in many types of parenchyma, e.g. hind-
brain [77], astrocytes [78], tumor [27,37], and skeletal
muscle [79]. On the other hand, degradation may be
due to the action of VEGF-degrading proteases, possibly
the same proteases that also initially cleave VEGF;
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with developmental systems where VEGF cleavage has
not been detected [17]. An interesting possibility that
has recently been raised is that of VEGF inhibition by
soluble VEGF inhibitors, e.g. sVEGFR1 [11,33] or con-
nective tissue growth factor [32], operating in an iso-
form-dependent manner through either HSPG
complexation or through NRP1 complexation. Interest-
ingly, each of these mechanisms also supports the ability
of proteases to allow VEGF to escape degradation,
through either HSPG binding or NRP1 binding, mediat-
ing VEGF redistribution. An important uncertainty in
VEGF catabolism is whether endothelial cells represent
the primary source of VEGF receptors and degradation
in vivo or not. For example, while the background
neural progenitor cells in the hindbrain may express
NRP1 [78], endothelial expression is typically thought to
be very strong [80]. Furthermore, immunochemical
staining usually shows that VEGF concentrations dimin-
ish precisely at the vascular front [12,13].
Besides being able to reproduce experimental observa-
tions of VEGF patterning in vivo, is there evidence for
isoform-specific degradation in tissues? VEGF (specifi-
cally, VEGF bioactivity) has been shown to degrade in
vitro under cell culture conditions [53,81] and in fact,
proteases that cleave VEGF into shorter isoforms also
seem to degrade it further [51,82]. In addition, while
VEGF degradation has not typically been studied as a
cause of VEGF patterning, this view is commonly
accepted in numerous developmental systems (e.g.
Decapentaplegic, Wingless in Drosophilia) [52,83,84].
Evidence for isoform-specific degradation however may
come from an indirect source. Perlecan knockdown in
zebrafish establishes a diffusible VEGF phenotype [85].
Surprisingly, it also increased total tissue VEGF levels.
Relevant to the present study is the fact that total VEGF
levels did not decrease, supporting the view that HSPGs
may be important mediators of VEGF degradation.
However, there are other pieces of evidence that seem
to contradict isoform-specific degradation: intrave-
nously-injected bevacizumab shows significantly greater
tumoral deposition in VEGF189-expressing tumors com-
pared to VEGF165 tumors and VEGF121 tumors [86].
Preliminary computational results suggest that this
observation supports the HSPG-binding-only model on
the basis of the total number of bevacizumab binding
sites, i.e. VEGF, increases proportionally to the VEGF
isoform matrix affinity.
An interesting prediction of the isoform-specific
degradation model is that the extracellular residence
times of different VEGF isoforms are roughly equal.
Thus, a test of the model can be made by injecting
labeled VEGF isoforms into tissues and measuring their
half-lives in the interstitial fluid or lymph. If this test
shows that the longer isoforms have significantly greater
residence times in tissues, it would disprove the iso-
form-specific degradation model. The residence time of
VEGF in tissues is a direct measure of the overall degra-
dation and clearance rate, and its constancy is identical
to the statement that the total levels of VEGF in tissue
are roughly constant against differences in patterns of
isoform secretion and VEGF proteolysis, a finding that
is suggested by results in [7,19]. Note that this state-
ment, however, does not contradict isoform-specific
degradation. In this model, the rate of degradation (or
clearance) of the soluble fraction of VEGF is isoform
specific, with heavier isoforms showing more rapid
degradation; however, accounting for all phases of
VEGF (e.g. matrix bound, receptor bound), the average
rate of degradation of any VEGF isoform is nearly iden-
tical (refer to Additional file 1, section S2).
Overall, our results form the basis for a different view of
VEGF patterning and endothelial behavior in response to
VEGF. The assumption behind how VEGF patterning is
intuitively interpreted is that of the transient: transiently,
MMPs elicit VEGF release, which can increase VEGF
receptor signaling on endothelial cells [16], and HSPGs do
hinder diffusion, forming isoform-specific differences in
soluble VEGF patterning. However, this assumption
ignores what happens to the VEGF distribution over much
longer periods of time, which are likely just as important
for slowly evolving processes such as vascular patterning.
The transient assumption only seems valid in studying in
vitro systems, systems where VEGF is cleared very slowly
[66]. On the other hand, in vivo systems seem to represent
a major phenomenological difference due to their much
more rapid VEGF dynamics (τ < 1 h, Appendix A1), neces-
sitating a steady-state analysis. Several additional assump-
tions have also been made in our analysis (Table 1). For
example, we assumed that the intrinsic proteolytic cleavage
rate of all isoforms is identical. However, experimental stu-
dies indicate that VEGF189 m a yb em o r er e s i s t a n tt o
MMPs than VEGF165 [7]. This point is interesting to note
since another study, [51], found that VEGF111 (a form of
VEGF also resistant to degradation or cleavage) also results
in angiogenesis with high vascular density [51], similar to
VEGF164Δ108-118 formed vessels [7]. Since the inability to be
further cleaved/degraded may be the common theme, it
may indicate that an inability to be cleaved/degraded alter-
nately underlies higher vascular densities in those systems.
Finally, in the current study, we specifically tested HSPG
binding as the mechanism of isoform specificity in VEGF
degradation. However, our results do not change if the iso-
form-specific degradation occurs solely through soluble
VEGF being degraded in an isoform-specific manner (not
shown), such as in a NRP1-dependent fashion.
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In the present study, we have identified a general
mechanism of VEGF transport that explains experimen-
tal data regarding VEGF isoform patterning and proteo-
lytic release at steady state, that of isoform specific
degradation. We have further highlighted possible
mechanisms by which information in the VEGF distri-
bution can be used to guide vascular patterning in an
attempt to explain vascular branching complexity and
also the regulation of angiogenesis and tumor growth by
proteases. A major limitation of our present study is
that we were only able to broadly consider isoform
ordering with respect to one or two features of the
VEGF distribution. Instead, sprout formation and the
subsequent patterning may be the result of a complex,
temporal orchestration of multiple extracellular VEGF
fractions, receptor signaling states, and cell types. Such
an analysis is outside the scope of our study, however
rule-based cell models and other modeling efforts are
being developed to the sophistication required to
address the multifactorial problem of vascular pattern-
ing, e.g. [87-89]. Many studies implement VEGF degra-
dation and/or ECM binding and proteolysis [90-93]
however not in a form, that as we show, gives rise to
differential VEGF gradients seen in vivo [13]. We believe
that the advances made in our study, specifically the
necessity of a mechanism of isoform-specific degrada-
tion, would be useful to such studies to improve the
predictions of the VEGF distribution.
Important biological questions remain to be addressed,
especially regarding the existence and nature of isoform-
specific VEGF degradation, the nature of the MMP
induced angiogenic switch, and the possible role of soluble
inhibitors such as sVEGFR1 in sprout formation, isoform
patterning, and in the protease-mediated angiogenic
switch.
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